Navigation Links
Misonix Announces Attendance At XIV World Congress of Neurological Surgery
Date:9/3/2009

FARMINGDALE, N.Y., Sept. 3 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has announced its attendance at the XIV World Congress of Neurological Surgery, August 30 - September 4, 2009 in Boston, Massachusetts. The World Congress, which is held every 4 years, is sponsored by the World Federation of Neurosurgical Societies ("WFNS"). Approximately 3,000 neurosurgeons from around the world were in attendance.

Founded in 1955, the WFNS is a professional, scientific, non-governmental organization comprised of 5 Continental Associations, 98 National Neurosurgical Societies and 6 Affiliate Societies, representing some 30,000 neurosurgeons worldwide. Key components of their mission are to exchange and disseminate knowledge and encourage research while implementing, improving and promoting standards of neurosurgical care.

The Company exhibited and demonstrated its SonaStar(R) Ultrasonic Surgical Aspiration System and its BoneScalpel(TM) Ultrasonic Bone Cutting System to the attending delegates. In addition, the Company's product presentations were filmed by WFNS representatives and will be featured on their website for approximately 1 year. Company presentations will be added to the site on or about October 1, 2009 and will be accessible at www.wfns.org/virtualexhibithall.

The SonaStar is used by Neurosurgeons and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, the Company's OsteoSculpt(TM) bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.

"Misonix is pleased to demonstrate its commitment to the neurosurgery community by supporting important educational programs like WFNS," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "We believe our SonaStar and BoneScalpel product platforms can make important contributions to improving neurosurgical patient outcomes."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward-looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

    Investor Relations Contact:
    Cameron Associates, Inc.
    Kevin McGrath
    212-245-4577
    Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix To Present at The Rodman & Renshaw 10th Annual Healthcare Conference
2. Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study
3. Misonix Schedules First Quarter Fiscal Year 2009 Financial Results Conference Call; November 13, 2008 at 4:30 P.M. Eastern
4. Misonix Reports First Quarter Fiscal Year 2009 Financial Results
5. Misonix Announces Extension and Expansion of Distribution Agreement With Mentor Corporation
6. Misonix Announces New HIFU Distribution Agreement for Italy
7. Misonix Schedules Second Quarter Fiscal Year 2009 Financial Results Conference Call; February 9, 2009 at 4:30 P.M. Eastern
8. Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008
9. Misonix Announces New Distribution Agreement for Israel
10. Misonix Announces New Sales Agency Agreement for Eastern Europe
11. Misonix Announces New Distribution Agreement for Belgium and Luxembourg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2016)... ... December 10, 2016 , ... The Pennsylvania Athletic ... joined forces with other healthcare organizations to promote diabetes education at the World ... featured a variety of speakers from around the Commonwealth of Pennsylvania. Speakers ...
(Date:12/9/2016)... ... December 09, 2016 , ... Groth Family Insurance, a Washington-based ... is initiating a charity drive to support the family of Cindy Hendrickson, a ... , On October 29th of this year, Cindy Hendrickson swerved to avoid ...
(Date:12/9/2016)... ... 2016 , ... The Justin Veatch Fund announced Thursday that ... film Whispering Spirits and its discussion guide for use by all of ... in the war against teen drug abuse. NCADD is the oldest anti-addiction advocacy ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name Medical ... York, NY, on December 3rd, to benefit Holy Name Medical Center's programs and ... which raised over $1 million - the largest event in the Center's history, ...
(Date:12/8/2016)... ... 08, 2016 , ... The West Virginia Medical Institute (WVMI) ... The name change aligns the entire company with its existing Quality Insights branded ... “We are very proud of the achievements associated with the West Virginia Medical ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Texas , Dec. 9, 2016  RxWiki Inc., ... apps, and digital marketing strategies of thousands of pharmacies ... it won Austin Inno,s "50 on Fire" ... "We,re pleased to accept the award as ... Loughlin , Chief Executive Officer at RxWiki. "Our platform ...
(Date:12/9/2016)... , Dec. 9, 2016  Forge Therapeutics, ... AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) ... ,LpxC, for the treatment of bacterial infections including ... been recognized as an attractive antibacterial target for ... lack of suitable chemical starting points has hampered ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... Patient ... loss of blood during surgeries, lowering the risks of neurological ... risks of SSIs. The patient warming systems can be segmented ... systems.These benefits in turn reduce the stay at hospitals thus, ...
Breaking Medicine Technology: